What is new/unknown about Transgenomic's tests being used as an accurate genetic alternative for cancer identification? Just trying to hone in on what the catalyst is here? Abstracts have been out since mid May and there hasn't been any volume spike that would indicate increased interest or anticipation of new data being released. Furthermore, I can't find any indication in the company PR's or presentations that ASCO is a major data release event for them. If there is something else out there, please illuminate me.
Thanks & GLTA,
Murocman
News 
Market Data 
Discover 
